about
Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs.Quantitative Expression and Co-Localization of Wnt Signalling Related Proteins in Feline Squamous Cell Carcinoma.Breed-predispositions to cancer in pedigree dogs.The clinical presentation and histopathologic-immunohistochemical classification of histiocytic sarcomas in the Flat Coated Retriever.Prognostic histopathological and molecular markers in feline mammary neoplasia.A retrospective review of treatment and response of high-risk mast cell tumours in dogs.Chromosome rearrangements in canine fibrosarcomas.Karyotype of canine soft tissue sarcomas: a multi-colour, multi-species approach to canine chromosome painting.COMPARISON OF TWO COARSE FRACTIONATED RADIATION PROTOCOLS FOR THE MANAGEMENT OF CANINE PITUITARY MACROTUMOR: AN OBSERVATIONAL STUDY OF 24 DOGS.Feline mediastinal lymphoma: a retrospective study of signalment, retroviral status, response to chemotherapy and prognostic indicators.Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid.Breed predispositions in canine mast cell tumour: a single centre experience in the United Kingdom.Limb salvage for primary malignant bone tumour.Treatment of canine lymphoma by veterinarians in first opinion practice in England.Evaluation of variants of melanoma-associated antigen genes and mRNA transcripts in melanomas of dogs.Immune-mediated haemolytic anaemia associated with a sarcoma in a flat-coated retriever.Complete Resolution of a Recurrent Canine Anal Sac Squamous Cell Carcinoma with Palliative Radiotherapy and Carboplatin Chemotherapy.Breed incidence of lymphoma in a UK population of insured dogs.Glycolysis inhibition improves photodynamic therapy response rates for equine sarcoids.Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors.Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers.Treatment of intranasal lymphoma in a horse by radiotherapy.An immunohistochemical study of the expression of the hypoxia markers Glut-1 and Ca-IX in canine sarcomas.Photodynamic therapy and diagnosis: Principles and comparative aspects.T Lymphocytes in Histiocytic Sarcomas of Flat-Coated Retriever Dogs.Expression of Fibroblast Activating Protein and Correlation with Histological Grade, Mitotic Index and Ki67 Expression in Canine Mast Cell Tumours.Comparison between Ki-67 index and mitotic index for predicting outcome in canine mast cell tumours.Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma.Idiopathic sterile pyogranuloma in three domestic cats.COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy*†Malignant histiocytosis in three Bernese mountain dogsRadiological assessment of severity of canine nasal tumours and relationship with survivalRadiotherapy of oral malignant melanomas in dogsUse of tamoxifen in the control of canine mammary neoplasiaResponse of 145 spontaneous canine head and neck tumours to radiation versus radiation plus microwave hyperthermia: results of a randomized phase III clinical studyEquine referrals for two ongoing studiesHistopathological survey of neoplasms in flat-coated retrievers, 1990 to 1998Squamous cell carcinoma of the nasal planum in 17 dogsDevelopment of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogsThe changing face of cancer treatment
P50
Q33488731-25FAB63B-0B9B-4CD0-93C8-33F7D9A59631Q36112545-9E6C0E44-33AD-402B-8827-C786616DD6CAQ36857180-8EF3A454-AFE2-4FC1-A09D-DF63453BA1ABQ37798623-DDCD46AD-783B-4BCB-A42F-E1F43EEDECCBQ38030206-ACDB3167-0600-40B8-8BC2-DE62C19004B6Q38249785-557D5691-08C4-4C5F-8E0C-480D9255CE63Q38471339-89609EBE-AE37-44A8-B493-F3A2F43908B9Q38475222-7DD69604-CB40-4FC9-A560-E1D6DCB3F7F7Q38989546-837614F7-3186-4FA5-BFDC-8B7FE9A2777CQ42247336-2B2E7B7A-7A5B-42ED-B303-AC82E47CB884Q43591426-AD168F6E-D106-4F00-80C0-1185F24B85F6Q43631608-205CE079-6D8D-476A-8FC6-08A0304F39DDQ43892454-4A96498D-466B-4045-A6D5-7BAB47D182C1Q44011445-DC3891D0-3426-427E-A2D7-73284660499DQ44371994-34751768-F7DA-4F3F-B795-C0593638B558Q44751157-20EDACB3-22B2-40C9-AD03-1AACC8DA9670Q47102574-6BB85C79-D5F3-4A87-AA2B-83F802A91433Q47363042-427736A4-10D1-417A-A9AC-AD32219A9C39Q48305205-1ED9EAF7-E0E3-4DB9-95B3-E34E290E4913Q49310990-29452E22-01C4-4A25-A619-1C172533E91CQ49594154-B88639C2-ABB5-4CB8-97C0-2170728750A3Q49613863-7D3130D5-5487-4A61-A4C9-2FFC7AA48891Q51031708-B1467472-AC09-4791-BEA0-2409642FE2EFQ51149440-5F54C316-5128-4E6C-97F6-423B3C4EC3B9Q51165902-78CA265B-03F8-4129-B8D5-0B6DB43FCCCAQ51302646-47EC3399-5EA5-48DB-AB70-F7B977350EAFQ53232375-3459972E-D55F-49FB-93BD-45818C556D0DQ53393113-434DD89B-F1E0-4A91-A364-580C2AC4CB98Q54211571-A4F12988-F038-438A-8936-900F41DF13BAQ61935089-1B3ABF56-BEAF-402A-8CA8-433EC6240EB3Q64050575-490B92A3-859A-408A-B3BB-0C263E38255EQ71107370-412185EF-93A7-4880-8A1A-95097860DEF4Q71794071-47EFE6B3-F788-403D-900B-D9BC18D167E4Q72262519-A98E8F73-48F9-446C-9EDB-1C5FC068533CQ72334611-E05C40E5-561F-4B19-9D1B-11BB3668569EQ73086035-0A5BD7D7-6BB6-4567-A323-67F89E9640B9Q73092350-F6B5B873-2B8B-4620-8D93-2E44E9A41360Q73228641-87EA61C4-0034-4F0D-94A9-8250F437F77EQ73411484-52F01DE1-E18D-40AD-A5F1-74BE5C18A675Q73841856-9837F0E1-79A4-4AB2-9A2C-9FE5F57561AC
P50
description
researcher ORCID ID = 0000-0002-7121-014X
@en
name
Jane Margaret Dobson
@ast
Jane Margaret Dobson
@en
Jane Margaret Dobson
@es
Jane Margaret Dobson
@nl
type
label
Jane Margaret Dobson
@ast
Jane Margaret Dobson
@en
Jane Margaret Dobson
@es
Jane Margaret Dobson
@nl
prefLabel
Jane Margaret Dobson
@ast
Jane Margaret Dobson
@en
Jane Margaret Dobson
@es
Jane Margaret Dobson
@nl
P31
P496
0000-0002-7121-014X